Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

"Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing" was originally created and published by Medical ...

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors ...

In the Spring 2024 semester, Glucoguard was invited to participate in the MADO program through our ongoing relationship with ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.03 ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate ...